Paul Edick - Xeris Pharmaceuticals President CEO, Director
| XERS Stock | USD 3.35 0.19 5.37% |
CEO
Mr. Paul R. Edick is the President, Chief Executive Officer, Director of the Company. Prior to XERIS Pharmaceuticals, Mr. Edick was Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics, a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata was acquired by Actavis plc in November 2014. Prior to Durata, Mr. Edick was Chief Executive Office of Ganic Pharmaceuticals, a Warburg Pincus investment search vehicle, from 2008 to 2010. Before Ganic, Mr. Edick was Chief Executive officer of MedPointe Healthcare, Inc., a USbased specialty pharmaceutical company, a position he assumed in 2006, having been President of Pharmaceutical Operations since 2002. Mr. Edick led the growth of the business, the development of a clinical stage portfolio, and the Company was subsequently sold to Meda, AB of Sweden in 2007. Mr. Edick currently serves on the Board of Directors for NewLink Genetics Inc., Sucampo Pharmaceuticals, Neos Therapeutics, and PDL BioPharma . Mr. Edick has also previously served on a number of pharmaceutical and healthcare company boards including Circassia Pharmaceuticals Plc, Amerita Inc. and Informed Medical Communications. He was also Chairman of the Board of Life Cycle Pharma Ltd since 2018.
| Age | 68 |
| Tenure | 7 years |
| Address | 180 North LaSalle Street, Chicago, IL, United States, 60601 |
| Phone | 844 445 5704 |
| Web | https://www.xerispharma.com |
Xeris Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.087) % which means that it has lost $0.087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.1716) %, meaning that it created substantial loss on money invested by shareholders. Xeris Pharmaceuticals' management efficiency ratios could be used to measure how well Xeris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 8.67 in 2025, whereas Return On Tangible Assets are likely to drop (0.31) in 2025. At this time, Xeris Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 5.5 M in 2025, despite the fact that Net Tangible Assets are likely to grow to (84 M).Similar Executives
| Found 6 records | CEO Age | ||
| Brendan OGrady | Assertio Therapeutics | N/A | |
| Christophe Weber | Takeda Pharmaceutical Co | 59 | |
| Joseph Papa | Emergent Biosolutions | 69 | |
| Kaare Schultz | Teva Pharma Industries | 59 | |
| Kevin Gorman | Neurocrine Biosciences | 66 | |
| Richard Francis | Teva Pharma Industries | 57 | |
Management Performance
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.087 |
Xeris Pharmaceuticals Leadership Team
Elected by the shareholders, the Xeris Pharmaceuticals' board of directors comprises two types of representatives: Xeris Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xeris. The board's role is to monitor Xeris Pharmaceuticals' management team and ensure that shareholders' interests are well served. Xeris Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xeris Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD D, Senior Affairs | ||
| Beth JD, Chief Secretary | ||
| Steven Pieper, Chief Officer | ||
| Dr MBA, CoFounder Officer | ||
| Paul Edick, President CEO, Director | ||
| John Shannon, President COO | ||
| Paul JD, Senior Advisor | ||
| Kevin McCulloch, Chief Officer | ||
| Kendal Korte, Senior Resources | ||
| Brian Conner, SVP Officer | ||
| Allison Wey, Senior Communications |
Xeris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xeris Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.087 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 729.31 M | ||||
| Shares Outstanding | 149.08 M | ||||
| Shares Owned By Insiders | 3.92 % | ||||
| Shares Owned By Institutions | 43.96 % | ||||
| Number Of Shares Shorted | 9.52 M | ||||
| Price To Book | 3.34 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.